Document Detail


Prospects of Induced Pluripotent Stem (iPS) Cell Technology in Regenerative Medicine.
MedLine Citation:
PMID:  21210760     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Induced pluripotent stem (iPS) cells are derived from adult somatic cells via reprogramming with ectopic expression of four transcription factors (Oct3/4, Sox2, c-Myc and Klf4; or, Oct3/4, Sox2, Nanog and Lin28), by which the resultant cells regain pluripotency, namely, the capability exclusively possessed by some embryonic cells to differentiate into any cell lineage under proper conditions. Given the ease in cell sourcing and a waiver of ethical opponency, iPS cells excel embryonic pluripotent cells in the practice of drug discovery and regenerative medicine. With an ex vivo practice in regenerative medicine, many problems involved in conventional medicine dosing, such as immune rejection, could be potentially circumvented. In this article, we briefly summarize the fundamentals and status quo of iPS related applications, and emphasize the prospects of iPS technology in regenerative medicine.
Authors:
Feng Zhang; Fudiman Citra; Dong-An Wang
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-7
Journal Detail:
Title:  Tissue engineering. Part B, Reviews     Volume:  -     ISSN:  1937-3376     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101466660     Medline TA:  Tissue Eng Part B Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Singapore, Singapore; LIVEZHAN0176@e.ntu.edu.sg.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polyelectrolyte multilayers in tissue engineering.
Next Document:  Next generation of electrosprayed fibers for tissue regeneration.